Management of High VLDL Levels

Risk Stratification and Treatment Thresholds

• The American College of Cardiology recommends initiating statin therapy as first-line treatment for patients with elevated VLDL and ASCVD risk ≥7.5%, while addressing lifestyle factors and secondary causes 1
• VLDL carries excess triglycerides in the range of 175-499 mg/dL and is atherogenic similar to LDL 1
• For adults 40-75 years with ASCVD risk ≥7.5%, reevaluate risk after addressing lifestyle and secondary factors, then consider persistently elevated triglycerides as favoring statin initiation or intensification 1
• Patients with moderate hypertriglyceridemia generally have multiple ASCVD risk factors including obesity, metabolic syndrome, and hyperglycemia 1
• Both elevated VLDL and chylomicrons are present in severe hypertriglyceridemia (≥500 mg/dL), raising ASCVD risk and pancreatitis risk, respectively 1

Primary Treatment Algorithm

• The American College of Cardiology recommends screening for triglyceride-raising medications, such as oral estrogens, tamoxifen, and beta blockers, as part of the primary treatment algorithm 1
• Evaluate for metabolic syndrome, obesity, diabetes, hypothyroidism, and excessive alcohol intake as part of the primary treatment algorithm 1, 2
• Assess glycemic control, as improved glucose management can lower triglyceride levels, with a strength of evidence based on clinical trials 3
• Higher-fat, lower-carbohydrate diets produce greater triglyceride reduction than lower-fat, higher-carbohydrate diets, with a strength of evidence based on clinical trials 2
• Very-low-carbohydrate diets show the greatest triglyceride reduction, with levels inversely associated with carbohydrate intake, and a strength of evidence based on clinical trials 2
• Replace 1% energy from saturated fatty acids with polyunsaturated fatty acids (PUFAs) to lower triglycerides by 0.4 mg/dL, with a strength of evidence based on clinical trials 2
• Weight loss of 1 kg/week can decrease triglycerides by 30-40%, while a weight loss of 0.25-0.5 kg/week can decrease triglycerides by 10-20%, with a strength of evidence based on clinical trials 2
• Intermittent fasting can reduce triglycerides 16-42%, with the greatest decreases associated with the greatest weight loss, and a strength of evidence based on clinical trials 2
• Individualized lifestyle intervention can achieve 48% triglyceride reduction regardless of lipid-lowering medications, with a strength of evidence based on clinical trials 2

Pharmacotherapy Selection

• The American College of Cardiology recommends initiating statin therapy as first-line for moderate hypertriglyceridemia with ASCVD risk, which reduces VLDL similarly to fibrates and has proven ASCVD risk reduction 1
• Atorvastatin 10-20 mg daily is recommended as initial therapy, providing 35.7-52.2% LDL reduction and triglyceride lowering, with a strength of evidence based on clinical trials 4
• Target at least 30-40% reduction in LDL-C when using statins in high-risk patients, with a strength of evidence based on clinical trials 5
• Continue statin therapy for ASCVD risk reduction in severe hypertriglyceridemia, and add fenofibrate if triglycerides remain ≥500 mg/dL despite lifestyle changes and statin therapy, particularly to prevent pancreatitis, with a strength of evidence based on clinical trials 1
• Fenofibrate can be combined with statins, but avoid gemfibrozil due to increased myopathy risk, with a strength of evidence based on clinical trials 4

Monitoring and Follow-Up

• Recheck lipid panel 4-6 weeks after initiating or changing therapy, with a strength of evidence based on clinical trials 7, 4
• If LDL goal not achieved on atorvastatin 10-20 mg, increase to 40 mg daily, with a strength of evidence based on clinical trials 4
• If target still not met, consider adding ezetimibe 10 mg daily for additional 15-20% LDL reduction, with a strength of evidence based on clinical trials 4
• Monitor for statin-associated side effects including muscle pain, liver enzyme elevation, with a strength of evidence based on clinical trials 7

Secondary Target: Non-HDL Cholesterol

• Non-HDL cholesterol represents the total pool of atherogenic lipoproteins including VLDL remnants, with a strength of evidence based on clinical trials 8
• For patients with triglycerides ≥200 mg/dL, target non-HDL cholesterol <130 mg/dL (30 mg/dL higher than LDL goal), with a strength of evidence based on clinical trials 8
• Non-HDL cholesterol is highly correlated with apolipoprotein B and has strong predictive power for coronary events, with a strength of evidence based on clinical trials 8